Medical Genetics

Medical genetics is the branch of medicine that deals with inherited disease: how changes in DNA are passed down families, how they produce illness, and how clinicians can diagnose, predict, prevent, and sometimes treat them.

11 frameworks, from 1900 to today · Genomics · Natural Sciences

still a working view ended · each leads to its entry below

Overview

Medical genetics is the branch of medicine that deals with inherited disease: how changes in DNA are passed down families, how they produce illness, and how clinicians can diagnose, predict, prevent, and sometimes treat them1. Its practitioners are physicians and counsellors who read family trees, order tests, and interpret genomes for patients1. What is at stake is concrete: whether a family learns that a child will develop a fatal disorder, whether a cancer can be caught early, whether a drug will work or poison. The field's history is the story of how inherited disease moved from something observed in families to something read in molecules—and of the tools that made that move possible.

Cataloguing the Inborn Errors of Metabolism

The scientific study of inherited disease begins with Archibald Garrod, a London physician who in 1902 described alkaptonuria, a rare condition in which urine turns black on standing. Garrod noticed that the condition ran in families, often among the children of first cousins, and reasoned that it behaved like a recessive trait. He proposed that patients lacked an enzyme needed to break down a normal metabolic intermediate, and in a series of lectures published as Inborn Errors of Metabolism (1909) he extended the idea to albinism, cystinuria, and pentosuria. Garrod's insight—that a gene specifies an enzyme and a defective gene produces a metabolic block—was decades ahead of its proof, but it established the founding logic of the field: inherited disease is a chemical defect with a family pattern.

Cytogenetics: Counting and Reading Chromosomes

For the first half of the twentieth century, human genetics was largely a science of pedigrees, because human chromosomes were hard to see. That changed in 1956, when Joe Hin Tjio and Albert Levan, working in Lund, reported that human cells contain 46 chromosomes—correcting a long-standing belief in 48. The technique that made this possible, treating cells so chromosomes spread and stain distinctly, opened cytogenetics: the study of chromosomes under the microscope.

The payoff came fast. In 1959, Jérôme Lejeune described an extra copy of chromosome 21 in Down syndrome, the first human disorder tied to a visible chromosomal abnormality. In the same year, abnormalities of the sex chromosomes were linked to Turner and Klinefelter syndromes. Later refinements—banding techniques in the late 1960s that gave each chromosome a recognizable stripe pattern, and in the 1980s fluorescence in situ hybridization (FISH), which lit up specific DNA sequences on chromosomes—turned cytogenetics into a routine diagnostic service. It could detect whole-chromosome errors, deletions, and translocations, but not the single-letter changes that cause most Mendelian disease.

Pedigrees, Nosology, and the Gene Catalogue

Alongside cytogenetics, clinical geneticists built a discipline of careful family study. Mendelian pedigree analysis—drawing family trees and testing whether a trait's transmission fits dominant, recessive, or sex-linked patterns—became the field's core reasoning tool. It let clinicians predict recurrence risks and distinguish inherited from sporadic disease. Victor McKusick at Johns Hopkins began in the 1950s to compile inherited conditions systematically, publishing Mendelian Inheritance in Man in 1966; the catalogue, later online as OMIM, grew into the field's reference map of thousands of disorders. This nosology—the systematic classification of disease—mattered because a named, well-characterized syndrome could be recognized in the next family and eventually traced to a gene.

Molecular Cloning and the Hunt for Genes

The decisive turn came with recombinant DNA in the 1970s. Restriction enzymes, which cut DNA at specific sequences, and molecular cloning, which copies a DNA fragment in bacteria, gave researchers the ability to isolate and study individual human genes2. The first disease gene found this way was for sickle-cell anemia: in 1978, using a globin gene probe, researchers showed that the causative mutation abolished a restriction site, a direct DNA diagnosis of a Mendelian disorder.

Finding genes whose protein product was unknown required a different strategy. Positional cloning—locating a gene purely by its chromosomal position, without knowing what it made—was the answer3. Linkage mapping first placed a disease locus relative to known markers in families; then chromosome walking closed in on the gene3. The method scored its landmark success in 1987, when Louis Kunkel's group cloned the gene for Duchenne muscular dystrophy, and again in 1989 with the cystic fibrosis gene, found by a multi-group effort led by Lap-Chee Tsui and Francis Collins. These were hard, slow campaigns, but they proved that any Mendelian disease gene could in principle be found.

Predictive and Prenatal Testing

Once a gene and its mutations were known, testing became possible. Carrier testing could identify unaffected people who carried one copy of a recessive mutation. Prenatal diagnosis, using fetal cells from amniocentesis or chorionic villus sampling, could tell parents whether a fetus was affected. Predictive testing could tell a healthy adult whether they carried a mutation that would later cause disease—most famously for Huntington's disease, whose gene was mapped in 1983 and cloned in 1993. These tests raised questions no laboratory could answer alone: whether to test, whom to tell, and what a result meant for relatives. That is where genetic counselling emerged as a clinical profession, distinct from laboratory genetics, concerned with explaining risk, supporting decisions, and protecting confidentiality. Its professional bodies and training programs took shape from the 1970s onward.

Cancer Genetics

Cancer genetics grew from two directions. Clinically, physicians noticed families with striking clusters of early-onset breast, ovarian, and colon cancer, and pedigree analysis suggested inherited susceptibility. Positional cloning identified the genes: APC for familial adenomatous polyposis in 1991, BRCA1 in 1994 and BRCA2 in 1995 for hereditary breast and ovarian cancer. Testing for these mutations let carriers choose intensified screening or preventive surgery. In parallel, tumor genetics showed that cancers arise through accumulated mutations in oncogenes and tumor-suppressor genes, so that the same molecular logic explained both inherited risk and sporadic tumors.

Pharmacogenomics

A separate thread asked why the same drug helps one patient and harms another. The field of pharmacogenetics—later pharmacogenomics when it scaled to whole-genome methods—traced drug responses to inherited variation in enzymes that metabolize drugs. The classic case is the gene CYP2D6, whose variants make some people poor metabolizers and others ultrarapid, changing how they handle many common medicines. The aim, still only partly realized in the clinic, is to choose drugs and doses by genotype rather than by trial and error.

The Genomic Era and Variant Interpretation

The Human Genome Project, completed in draft in 2001 and to high accuracy in 2003, changed the economics of gene discovery. Massively parallel sequencing, introduced around 2005, could read millions of DNA fragments at once, and by the 2010s whole-exome sequencing (reading just the protein-coding portion of the genome) and whole-genome sequencing became affordable enough for diagnosis. Clinical genomics shifted the question from "can we find the gene?" to "what does this variant mean?" Variant interpretation became a discipline of its own: comparing a patient's variant against population databases, family segregation, and functional evidence, and classifying it on a scale from benign to pathogenic. The field's professional guidelines for this classification, issued by the American College of Medical Genetics and Genomics and updated with the Association for Molecular Pathology, standardized what had been ad hoc judgment.

Complex Disease and Polygenic Genetics

Most common disease—diabetes, heart disease, most cancers—does not follow Mendelian patterns. The tools for this were genome-wide association studies (GWAS), which from 2005 onward compared hundreds of thousands of common variants between cases and controls to find statistical associations. GWAS revealed that common diseases are influenced by many variants of small effect, and polygenic risk scores now sum those effects into a single number4. How useful such scores are in the clinic, and how they perform across ancestries, remains an open and actively debated question.

Where the Field Stands

Today medical genetics runs on clinical genome and exome sequencing, chromosomal microarray (a higher-resolution successor to karyotyping), and increasingly on rapid sequencing in newborn and critical-care settings. Genetic counselling is embedded in cancer, prenatal, cardiac, and pediatric care. The unresolved questions are real: how to interpret the thousands of variants of uncertain significance that sequencing turns up, how to make polygenic risk useful without widening health disparities, and how to deliver genomic medicine equitably beyond the well-resourced centers where it was built.

References

  1. Medical genetics (introduction, Scope, Genetic counseling), Wikipedia
  2. Molecular cloning (introduction, History), Wikipedia
  3. Genetic screen (Positional cloning), Wikipedia
  4. Polygenic score, Wikipedia

The frameworks of Medical Genetics

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1900-Present
  2. 1902-1960

    Inborn Errors of Metabolism

    How do defective genes cause metabolic disease?

    Fly to its tower in Nousfarer

  3. 1956-Present

    Cytogenetics

    What do chromosomes look like and how do they go wrong?

    Fly to its tower in Nousfarer

  4. 1960-Present

    Pharmacogenomics

    Why do people respond differently to drugs?

    Fly to its tower in Nousfarer

  5. 1966-Present
  6. 1970-Present

    Genetic counseling

    How should genetic risk be explained to families?

    Fly to its tower in Nousfarer

  7. 1970-Present

    Predictive and Prenatal Testing

    Can we know if a person will develop a genetic disease?

    Fly to its tower in Nousfarer

  8. 1980-2005

    Positional Cloning

    How can we find a disease gene without knowing its product?

    Fly to its tower in Nousfarer

  9. 1990-Present

    Cancer Genetics

    How do inherited mutations lead to cancer?

    Fly to its tower in Nousfarer

  10. 2005-Present
  11. 2005-Present

    Complex Disease and Polygenic Genetics

    How do many genes together influence common disease?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Mendelian Pedigree AnalysisInborn Errors of MetabolismCytogeneticsPharmacogenomicsClinical Nosology and the Gene Catalo…Genetic counselingPredictive and Prenatal TestingPositional CloningCancer GeneticsClinical Genomics and Variant Interpr…Complex Disease and Polygenic Genetics

Beyond the field

Where Medical Genetics's ideas came from in other fields, and what they led to there: the strongest 12 of 50 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Medical Genetics is a planet in Nousfarer

Its city has a tower for each of these 11 frameworks. Land, walk in, and climb one concept at a time.

Land on Medical Genetics

Related fields

Fields its ideas are linked to

More in Genomics

See where Medical Genetics sits on the Map of Human Knowledge